Efficacy and safety of intravenous belimumab in Japanese patients with systemic lupus erythematosus: A subgroup analysis of a phase 3 randomized placebo-controlled trial.

MLA

Yoshiya Tanaka, et al. “Efficacy and Safety of Intravenous Belimumab in Japanese Patients with Systemic Lupus Erythematosus: A Subgroup Analysis of a Phase 3 Randomized Placebo-Controlled Trial.” Modern Rheumatology, vol. 29, no. 3, May 2019, pp. 452–60. EBSCOhost, https://doi.org/10.1080/14397595.2018.1480915.

APA

Yoshiya Tanaka, Damon Bass, Myron Chu, Egginton, S., Beulah Ji, Struemper, H., & Roth, D. (2019). Efficacy and safety of intravenous belimumab in Japanese patients with systemic lupus erythematosus: A subgroup analysis of a phase 3 randomized placebo-controlled trial. Modern Rheumatology, 29(3), 452–460. https://doi.org/10.1080/14397595.2018.1480915

Chicago

Yoshiya Tanaka, Damon Bass, Myron Chu, Sally Egginton, Beulah Ji, Herbert Struemper, and David Roth. 2019. “Efficacy and Safety of Intravenous Belimumab in Japanese Patients with Systemic Lupus Erythematosus: A Subgroup Analysis of a Phase 3 Randomized Placebo-Controlled Trial.” Modern Rheumatology 29 (3): 452–60. doi:10.1080/14397595.2018.1480915.